Curcumin and dimethoxycurcumin induced epigenetic changes in leukemia cells.

Area of Science:

• Pharmacology
• Molecular Biology
• Epigenetics

Background:

• Curcumin is a promising chemopreventive and antitumor agent.
• Poor bioavailability and low stability limit curcumin's clinical use.
• Dimethoxycurcumin (DMC) is a synthetic analogue designed to improve upon curcumin's limitations.

Purpose of the Study:

• Compare the cytotoxicity, metabolism, and epigenetic effects of curcumin and DMC in leukemia cells.
• Investigate DMC's potential as an improved therapeutic agent.
• Explore the induction of epigenetic changes by these compounds.

Main Methods:

• Flow cytometry for apoptosis and cell cycle analysis.
• Real-time PCR for gene expression.
• DNA pyrosequencing for DNA methylation analysis.
• Human pooled liver microsomes for metabolic stability.
• Chromatin Immunoprecipitation for histone methylation quantification.

Main Results:

• Curcumin and DMC showed no cytotoxicity but induced G2/M cell cycle arrest in leukemia cells.
• DMC exhibited greater metabolic stability compared to curcumin.
• Neither compound demonstrated DNA hypomethylating activity.
• DMC increased expression of promoter-methylated genes and H3K36me3 marks without reversing DNA methylation.

Conclusions:

• DMC is a more stable curcumin analogue with distinct epigenetic effects.
• DMC can induce the expression of promoter-methylated genes.
• Combining DMC with DNA methyltransferase inhibitors may enhance epigenetic reprogramming for gene re-expression.